Clotilde Fuentes-Orozco, Sara Jazmín Garcia-Salazar, Benjamín Gómez-Navarro, Eduardo González-Espinoza, Alonso Zepeda-González, Juan Narciso Ramírez-Robles, Rafael Castañeda-Espinoza, Irinea Yáñez-Sánchez, Francisco Javier Gálvez-Gastelum, Gabino Cervantes-Guevara, Guillermo Alonso Cervantes-Cardona, Guadalupe Ivette Contreras-Hernández, Jacob Esau Pérez-Landeros, David García-Martinez, Alejandro González-Ojeda
Biomedical Research Unit 02, Specialties Hospital, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico
Ann Transplant 2018; 23:442-449
Recent studies have demonstrated that statins have anti-inflammatory and immunomodulatory properties, which could be considered beneficial in kidney transplantations. This study assesses the anti-inflammatory effect of atorvastatin on the kidney grafts of living donor transplants.
MATERIAL AND METHODS: In a randomized clinical trial, kidney donors were divided into 2 groups. The study group constituted 24 donors who received 40 mg atorvastatin, and 24 donors who received a placebo control, 4 weeks prior to transplantation. Serum C-reactive protein (CRP) levels were measured before and after atorvastatin administration. CRP and renal function of kidney recipients were measured at baseline and 1, 6, and 24 hours after transplantation.
RESULTS: After 4 weeks of treatment, the CRP level was 5.62±3.82 mg/dL in the control group and 3.27±0.62 mg/dL in the study group (P=0.007). Upon reperfusion, CRP levels in recipients at 1 hour were, 5.8±3.9 and 3.8±1.0 mg/dL, respectively (P=0.04). Twenty-four hours after the kidney transplantations, serum creatinine levels were 2.5±1.5 mg/dL in the study group and 3.7±2.4 mg/dL in the control group (P=0.04).
CONCLUSIONS: Our study suggests that the use of atorvastatin prior to allograft procurement of kidney transplant, reduces the acute kidney inflammatory burden profile, and promotes an improved kidney function recovery following transplantation.
Keywords: Anti-Inflammatory Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kidney Transplantation, Living Donors